Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
The DOI matches its Crossref record; 158 of the 169 references it cites were found in a registry or an index.
Abstract
Objective: To update the "Testosterone Therapy in Men With Androgen Deficiency Syndromes" guideline published in 2010. Participants: The participants include an Endocrine Society-appointed task force of 10 medical content experts and a clinical practice guideline methodologist. Evidence: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation approach to describe the strength of recommendations and the quality of evidence. The task force commissioned two systematic reviews and used the best available evidence from other published systematic reviews and individual studies. Consensus Process: One group meeting, several conference calls, and e-mail communications facilitated consensus development. Endocrine Society committees and members and the cosponsoring organization were invited to review and comment on preliminary drafts of the guideline. Conclusions: We recommend making a diagnosis of hypogonadism only in men with symptoms and signs consistent with testosterone (T) deficiency and unequivocally and consistently low serum T concentrations. We recommend measuring fasting morning total T concentrations using an accurate and reliable assay as the initial diagnostic test. We recommend confirming the diagnosis by repeating the measurement of morning fasting total T concentrations. In men whose total T is near the lower limit of normal or who have a condition that alters sex hormone-binding globulin, we recommend obtaining a free T concentration using either equilibrium dialysis or estimating it using an accurate formula. In men determined to have androgen deficiency, we recommend additional diagnostic evaluation to ascertain the cause of androgen deficiency. We recommend T therapy for men with symptomatic T deficiency to induce and maintain secondary sex characteristics and correct symptoms of hypogonadism after discussing the potential benefits and risks of therapy and of monitoring therapy and involving the patient in decision making. We recommend against starting T therapy in patients who are planning fertility in the near term or have any of the following conditions: breast or prostate cancer, a palpable prostate nodule or induration, prostate-specific antigen level > 4 ng/mL, prostate-specific antigen > 3 ng/mL in men at increased risk of prostate cancer (e.g., African Americans and men with a first-degree relative with diagnosed prostate cancer) without further urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia. We suggest that when clinicians institute T therapy, they aim at achieving T concentrations in the mid-normal range during treatment with any of the approved formulations, taking into consideration patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost. Clinicians should monitor men receiving T therapy using a standardized plan that includes: evaluating symptoms, adverse effects, and compliance; measuring serum T and hematocrit concentrations; and evaluating prostate cancer risk during the first year after initiating T therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TRT is also contra-indicated in people with (high risk of) prostate cancer, a history of breast cancer, thrombophilia, elevated hematocrit, untreated severe obstructive sleep apnea, uncontrolled heart failure, and myocardial infarction or stroke within the last 6 months [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It suppresses spermatogenesis, and thus, cannot be used in patients with a desire to have children in the near future.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“It may result in gynecomastia, acne, testicular atrophy and erythrocytosis.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“The Endocrine Society guideline emphasizes the importance of lifestyle changes in men with central hypogonadism and comorbidities [3].”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
In the citing paper
“Hyperprolactinemia also suppresses the secretion of GnRH and the response of gonadotropins to GnRH secretion.”
From Treatment of Men with Central Hypogonadism: Alternatives for Testosterone Replacement Therapy (2020) · cites this paper as [3]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2354 · Cited by 1,954
Self-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544
Self-citationAdverse Events Associated with Testosterone Administration
Basaria, S., Coviello, A. D., Travison, T. G., Storer, T. W., Farwell, W. R., Jette, A. M., Eder, R., Tennstedt, S., Ulloor, J., Zhang, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000485 · Cited by 1,494
Self-citationHeidenreich, A., Bastian, P. J., Bellmunt, J., Bolla, M., Joniau, S., van der Kwast, T., Mason, M., Matveev, V., Wiegel, T., Zattoni, F., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.002 · Cited by 1,341
Rosner, W., Auchus, R. J., Azziz, R., Sluss, P. M., & Raff, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1864 · Cited by 1,176 · cited 1×
“culated from TT, SHBG, and albumin levels (23, 24).”
Harrison's Principles of Internal Medicine
Massarelli, J. J. (1984) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1984.03340300091039 · Cited by 1,132
Research works printed but not linked: 1
- Bhasin, 2015, Disorders of the testes and male reproductive system
Cited by
Items 301–400 of 1,733
Theodorakis, N., Feretzakis, G., Vamvakou, G., Verykios, V. S., Polymeris, A., & Nikolaou, M. (2024) · Hormones · doi:10.1007/s42000-024-00587-2 · Cited by 28
Li, G., Qian, X.-D., Ma, C., & Yin, F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1035114 · Cited by 32
Effects of a Novel Oral Testosterone Undecanoate on Ambulatory Blood Pressure in Hypogonadal Men
White, W. B., Dobs, A. S., Carson, C. C., DelConte, A., Khera, M., Miner, M. M., Shahid, M. S., Kim, K., & Chidambaram, N. (2021) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484211027394 · Cited by 28
“Testosterone replacement therapy for male hypogonadism or testosterone deficiency is administered by intramuscular and subcutaneous injections, transdermal gels and lotions, dermal patches, intranasal gels, and more recently by oral formulations.(1) Oral formulations of testosterone undecanoate have been developed to…”
BackgroundHoward, E. E., Shankaran, M., Evans, W. J., Berryman, C. E., Margolis, L. M., Lieberman, H. R., Karl, J. P., Young, A., Montano, M. A., Matthews, M. D., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac295 · Cited by 37
Testicular Function of Childhood Cancer Survivors: Who Is Worse?
Duca, Y., Cataldo, A. D., Russo, G. M., Cannata, E., Burgio, G., Compagnone, M., Alamo, A., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122204 · Cited by 29
“According to Endocrine Society guidelines, testosterone must be measured in the morning after 8 h of fasting and the diagnosis must be confirmed repeating the blood sampling a second time under the same conditions [18].”
MethodPezzaioli, L. C., Quiros-Roldan, E., Paghera, S., Porcelli, T., Maffezzoni, F., Delbarba, A., Degli Antoni, M., Cappelli, C., Castelli, F., & Ferlin, A. (2021) · Infection · doi:10.1007/s15010-020-01558-6 · Cited by 27
The association of free testosterone levels with coronavirus disease 2019
Apaydın, T., Şahin, B., Dashdamirova, S., Yazan, C. D., Elbasan, O., Ilgın, C., Bilgin, H., Çam, K., Bahramzada, G., Kucuk, A., et al. (2022) · Andrology · doi:10.1111/andr.13152 · Cited by 30
“Alanine aminotransferase (U/L) 32 (8-217) 28”
Belladelli, F., Boeri, L., Pozzi, E., Fallara, G., Corsini, C., Candela, L., Cazzaniga, W., Cignoli, D., Pagliardini, L., d’Arma, A., et al. (2022) · Metabolites · doi:10.3390/metabo12020143 · Cited by 31
“Therefore, in the case of IR or insulin deficiency, spermatogenesis is altered and biopsies of diabetic patients revealed testicular impairments [31,32].”
BackgroundMotta, G., Zavattaro, M., Romeo, F., Lanfranco, F., & Broglio, F. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01702 · Cited by 28
A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial
Pencina, K. M., Burnett, A. L. “., Storer, T. W., Guo, W., Li, Z., Kibel, A. S., Huang, G. T.-W., Blouin, M., Berry, D. L., Basaria, S. S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab361 · Cited by 31
Self-citationTestosterone replacement in aging men: an evidence-based patient-centric perspective
Bhasin, S. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146607 · Cited by 32
Self-citationSmith, I., Salazar, I., RoyChoudhury, A., & St‐Onge, M. (2019) · Sleep Health · doi:10.1016/j.sleh.2019.07.003 · Cited by 30
“Hypogonadism, or low testosterone, in men leads to a wide range of sexual symptoms including erectile dysfunction, decreased sex drive, and decreased fecundity (1).”
BackgroundGoto, T., Hirabayashi, M., Watanabe, Y., Sanbo, M., Tomita, K., Inoue, N., Tsukamura, H., & Uenoyama, Y. (2020) · Endocrinology · doi:10.1210/endocr/bqaa092 · Cited by 30
Testosterone recovery therapy targeting dysfunctional Leydig cells
Garza, S., & Papadopoulos, V. (2022) · Andrology · doi:10.1111/andr.13304 · Cited by 31
The Oxytocin System and Implications for Oxytocin Deficiency in Hypothalamic-Pituitary Disease
Aulinas, A., & Lawson, E. A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf008 · Cited by 35
Działach, Ł., Sobolewska, J., Żak, Z., Respondek, W., & Witek, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1338345 · Cited by 39
Wang, C., Meriggiola, M. C., Amory, J. K., Barratt, C. L. R., Behre, H. M., Bremner, W. J., Ferlin, A., Honig, S. C., Kopa, Z., Lo, K. C., et al. (2023) · Andrology · doi:10.1111/andr.13525 · Cited by 37
Self-citationEffects of Bariatric Surgery in Male Obesity-Associated Hypogonadism
Rigon, F. A., Ronsoni, M. F., Hohl, A., & van de Sande-Lee, S. (2019) · Obesity Surgery · doi:10.1007/s11695-019-03829-0 · Cited by 27
Trends in testosterone prescription during the release of society guidelines
Sellke, N. C., Omil-Lima, D., Sun, H. H., Tay, K., Rhodes, S., Loeb, A., & Thirumavalavan, N. (2023) · International Journal of Impotence Research · doi:10.1038/s41443-023-00709-1 · Cited by 32
“In March of 2018, the Endocrine Society (ES) also released guidelines regarding TD, updating their prior guidelines from 2010 [8].”
BackgroundMethodChadid, S., Barber, J. R., Rohrmann, S., Nelson, W. G., Yager, J. D., Kanarek, N., Bradwin, G., Dobs, A. S., McGlynn, K. A., & Platz, E. A. (2019) · Journal of the Endocrine Society · doi:10.1210/js.2019-00178 · Cited by 30
“10 doi: 10.1210/js.2019-00178 | Journal of the Endocrine Society | 1825–1836 Symptoms accompanying testosterone deficiency are often treated with testosterone supplementation.”
BackgroundInfluentialXia, K., Chen, H., Wang, J., Feng, X. G., Gao, Y., Wang, Y., Deng, R., Wu, C., Luo, P., Zhang, M., et al. (2020) · Theranostics · doi:10.7150/thno.46854 · Cited by 27
“Epidemiological studies have suggested that low testosterone levels are associated with multiple diseases and deteriorated quality of life [10, 11].”
BackgroundHypogonadism and metabolic syndrome: review and update
Berg, W. T., & Miner, M. M. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000582 · Cited by 26
“The Endocrine Society set the lower limit of normal testosterone to 264 ng/dl [16].”
BackgroundWhite, W. B., Bernstein, J. S., Rittmaster, R. S., et al. (2021) · Journal of Clinical Hypertension · doi:10.1111/jch.14297 · Cited by 26
Do nothing but observe microprolactinomas: when and how to replace sex hormones?
Bonert, V. S. (2020) · Pituitary · doi:10.1007/s11102-020-01039-x · Cited by 44
Barake, M., Klibanski, A., & Tritos, N. A. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0667 · Cited by 30
Esteves, S. C., Achermann, A. P. P., Miyaoka, R., Verza, S., Jr., Fregonesi, A., & Riccetto, C. (2024) · Fertility and Sterility · doi:10.1016/j.fertnstert.2024.06.013 · Cited by 32
Neuroprotective Effects of Testosterone in the Hypothalamus of an Animal Model of Metabolic Syndrome
Sarchielli, E., Comeglio, P., Filippi, S., Cellai, I., Guarnieri, G., Marzoppi, A., Cipriani, S., Vignozzi, L., Morelli, A., & Maggi, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041589 · Cited by 30
“In fact, the clinical opportunity to treat MetS-related hypogonadism with TTh, although supported by some [60], but not all [61], meta-analyses, has been recently questioned [62], suggesting that lifestyle modifications, more than TTh, should be the first line of intervention in this condition.”
BackgroundThe Hypothalamic-Pituitary-Gonadal Axis in Men with Schizophrenia
Matuszewska, A., Kowalski, K., Jawień, P., Tomkalski, T., Gaweł-Dąbrowska, D., Merwid‐Ląd, A., Szeląg, E., Błaszczak, K., Wiatrak, B., Danielewski, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076492 · Cited by 40
“Symptoms include low testosterone levels, impaired spermatogenesis, and low gonadotropin levels [209,220].”
BackgroundGraybill, S. D., Hatfield, J., Kravchenko, M. I., Beckman, D., Tate, J. M., Beauvais, A., CLERC, P. G., Davila, D., Forbes, W. L., Wardian, J., et al. (2021) · Andrology · doi:10.1111/andr.12966 · Cited by 31
Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations
Jaschke, N., Wang, A., Hofbauer, L. C., Rauner, M., & Rachner, T. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101301 · Cited by 30
Obstructive Sleep Apnea and Testosterone Therapy
Payne, K. S., Lipshultz, L. I., Hotaling, J. M., & Pastuszak, A. W. (2020) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.04.004 · Cited by 29
Accurate measurement of total and free testosterone levels for the diagnosis of androgen disorders
Guzelce, E. C., Galbiati, F., Goldman, A. L., Gattu, A. K., Basaria, S. S., & Bhasin, S. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101683 · Cited by 30
Self-citationSantos, H. O., Howell, S. L., Nichols, K., & Teixeira, F. J. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.03.016 · Cited by 25
The Sexual Incentive Motivation Model and Its Clinical Applications
Ågmo, A., & Laan, E. T. M. (2022) · The Journal of Sex Research · doi:10.1080/00224499.2022.2134978 · Cited by 33
“Likewise, the observations showing that male hypogonadism leads to generalized sexual dysfunction have opened the way for androgen replacement therapy in men suffering from this condition (Bhasin et al., 2018).”
Iannone, M., Palermo, A., de la Torre, X., Romanelli, F., Sansone, A., Sansone, M., Lenzi, A., & Botrè, F. (2019) · Steroids · doi:10.1016/j.steroids.2019.108491 · Cited by 26
Optimizing sexual and reproductive health across the lifespan in people with cystic fibrosis
West, N. E., Kazmerski, T. M., Taylor‐Cousar, J. L., Tangpricha, V., Pearson, K., Aitken, M. L., & Jain, R. (2021) · Pediatric Pulmonology · doi:10.1002/ppul.25703 · Cited by 26
“In the evaluation of low testosterone, the Endocrine Society recommends distinguishing between primary (hypothalamic/pituitary) versus secondary (testicular) disease in the etiology of the hypogonadism.(77)”
BackgroundSalem, J., Bretagne, M., Lebrun‐Vignes, B., Waintraub, X., Gandjbakhch, E., Hidden‐Lucet, F., Gougis, P., Bachelot, A., & Funck‐Brentano, C. (2019) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2019.06.008 · Cited by 27
Leydig cell aging: Molecular mechanisms and treatments
Papadopoulos, V., & Zirkin, B. R. (2021) · Vitamins and hormones · doi:10.1016/bs.vh.2020.12.023 · Cited by 28
Jasuja, R., Pencina, K. M., Spencer, D. J., Peng, L., Privat, F., Dhillo, W. S., Jayasena, C. N., Hayes, F. J., Yeap, B. B., Matsumoto, A. M., et al. (2022) · Andrology · doi:10.1111/andr.13310 · Cited by 26
Self-citationHaring, R., Ghannad, M., Bertizzolo, L., & Page, M. J. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.02.004 · Cited by 27
Lapauw, B., & Kaufman, J. (2020) · European Journal of Endocrinology · doi:10.1530/eje-20-0394 · Cited by 27
Sex-tailored pharmacology and COVID-19: Next steps towards appropriateness and health equity
Spini, A., Giudice, V., Brancaleone, V., Morgese, M. G., Francia, S. D., Filippelli, A., Ruggieri, A., Ziche, M., Ortona, E., Cignarella, A., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105848 · Cited by 26
“Plasma T levels decrease in elderly men and in the presence of highly prevalent comorbidities in COVID-19 such as obesity and diabetes [24].”
GREEN, D. J., Chasland, L. C., Yeap, B. B., & Naylor, L. H. (2024) · Sports Medicine - Open · doi:10.1186/s40798-024-00703-x · Cited by 34
“It is pertinent to note that this review was not powered to assess any potential cardiovascular (CV) or cancer risks of T treatment in men and the use of T is still only indicated clinically for men with pathological androgen deficiency (disorders of the hypothalamus, pituitary or testes) [18, 62].”
BackgroundAndrogens and Parkinson's Disease: A Review of Human Studies and Animal Models
Bourque, M., Soulet, D., & Paolo, T. D. (2021) · Androgens Clinical Research and Therapeutics · doi:10.1089/andro.2021.0011 · Cited by 33
“Testosterone treatment in aging men with testosterone deficiency improved energy and had a modest effect on physical function.(48,49) Thus, as testosterone therapy can act directly on symptoms and signs associated with testosterone deficiency, it is unclear whether the improvements come from restoring”
BackgroundShores, M. M., Walsh, T. J., Korpak, A. M., Krakauer, C. A., Forsberg, C. W., Fox, A., Moore, K. P., Heckbert, S. R., Thompson, M. L., Smith, N. L., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.020562 · Cited by 26
Self-citationObesity, Body Composition, and Sex Hormones: Implications for Cardiovascular Risk
Singh, P., Covassin, N., Marlatt, K. L., Gadde, K. M., & Heymsfield, S. B. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210014 · Cited by 56
Pastuszak, A. W., Gittelman, M., Tursi, J. P., Jaffe, J. S., Schofield, D., & Miner, M. M. (2021) · Andrology · doi:10.1111/andr.13108 · Cited by 32
Grossmann, M., Jayasena, C. N., & Anawalt, B. D. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad180 · Cited by 27
Summary of the clinical practice manual for late‐onset hypogonadism
Ide, H., Akehi, Y., Fukuhara, S., Ohira, S., Ogawa, S., Kataoka, T., Kumagai, H., Kobayashi, K., Komiya, A., Shigehara, K., et al. (2023) · International Journal of Urology · doi:10.1111/iju.15160 · Cited by 29
Testosterone Use in Adolescent Males: Current Practice and Unmet Needs
Vogiatzi, M. G., Tursi, J. P., Jaffe, J. S., Hobson, S., & Rogol, A. D. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa161 · Cited by 29
“The current TRT options for adolescent males with CDGP and hypogonadism, and information on dosing, or lack thereof, are summarized in Table 1 [1, 15, 22, 25, 32, 36, 59, 60, 62-82].”
BackgroundInfluentialEfficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review.
Raheem, O. A., Chen, T., Akula, K. P., Greenberg, J., Le, T. V., Chernobylsky, D., Sikka, S. C., & Walsh, T. J. (2021) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2020.08.003 · Cited by 22
Santos, H. O., Cadegiani, F., & Forbes, S. C. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.06.006 · Cited by 28
Male hypogonadism: therapeutic choices and pharmacological management
Vignera, S. L., Izzo, G., Emerenziani, G. P., Cannarella, R., Condorelli, R. A., Calogero, A. E., & Aversa, A. (2020) · Minerva Endocrinology · doi:10.23736/s0391-1977.20.03195-8 · Cited by 24
Association of Male Hypogonadism With Risk of Hospitalization for COVID-19
Dhindsa, S., Champion, C. D., Deol, E. S., Lui, M., Campbell, R. G., Newman, J., Yeggalam, A., Nadella, S., Ahir, V., Shrestha, E., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.29747 · Cited by 24
“04 Testosterone, median (IQR), ng/dL 131 (18-187)a,b 381 (300-504) 396 (248-624) <.”
InfluentialPofi, R., Gunatilake, S. S. C., Macgregor, V., Shine, B. S. F., Joseph, R. N., Grossman, A. B., Isidori, A. M., Cudlip, S., Jafar‐Mohammadi, B., Tomlinson, J., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00406 · Cited by 26
Anabolic steroid users' misuse of non-traditional prescription drugs
Ip, E. J., Doroudgar, S., Lau, B., & Barnett, M. J. (2018) · Research in Social and Administrative Pharmacy · doi:10.1016/j.sapharm.2018.07.003 · Cited by 29
Garmes, H. M., Boguszewski, C. L., Miranda, P. A. C., Martins, M. R. A., Correa‐Silva, S. R., Abucham, J., Musolino, N. R. D. C., Vilar, L., Portari, L. H. C., Gadelha, M. R., et al. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000335 · Cited by 31
“Current guidelines recommend the use of minimal doses necessary to maintain testosterone levels in the range of 450–600 ng/dL (30,67).”
BackgroundMethodInfluentialAndrogens and Anemia: Current Trends and Future Prospects
Al‐Sharefi, A., Mohammed, A., Abdalaziz, A., & Jayasena, C. N. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00754 · Cited by 29
Vignera, S. L., Cannarella, R., Garofalo, V., Crafa, A., Barbagallo, F., Condorelli, R. A., & Calogero, A. E. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01425-9 · Cited by 39
Albright, J. A., Lou, M. Y., Rebello, E., Ge, J., Testa, E. J., Daniels, A. H., & Arcand, M. A. (2023) · Journal of Foot and Ankle Research · doi:10.1186/s13047-023-00678-0 · Cited by 28
“Low levels of serum sex hormones can have detrimental impacts on patient’s health, with presentation including sexual dysfunction and decreases in muscle mass, strength, bone density, libido, and concentration [6, 7].”
The complications of male hypogonadism: is it just a matter of low testosterone?
Munari, E. V., Amer, M., Amodeo, A., Bollino, R., Federici, S., Goggi, G., Giovanelli, L., Persani, L., Cangiano, B., & Bonomi, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1201313 · Cited by 25
Cannarella, R., Gusmano, C., Leanza, C., Garofalo, V., Crafa, A., Barbagallo, F., Condorelli, R. A., Vignera, S. L., & Calogero, A. E. (2023) · Asian Journal of Andrology · doi:10.4103/aja202352 · Cited by 37
“…treatment of hypogonadism, a clinical syndrome resulting from the failure of the testis to produce physiological testosterone concentrations, 1,2 and which, if left untreated, leads to poor quality of life causing loss of muscle mass and strength, sexual dysfunctions, osteoporosis, and,…”
BackgroundLiu, P. Y., Takahashi, P. Y., Yang, R. J., Iranmanesh, A., & Veldhuis, J. D. (2020) · SLEEP · doi:10.1093/sleep/zsaa008 · Cited by 22
“An early morning time window was examined because Te measurement for the assessment of hypogonadism should be performed in the early morning [2, 45].”
BackgroundTranscription regulation of NRF1 on StAR reduces testosterone synthesis in hypoxemic murine
Wang, X., Jin, L., Jiang, S., Wang, D., Lu, Y., & Zhu, L. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.04.019 · Cited by 23
Maione, L., Sarfati, J., Gonfroy‐Leymarie, C., Salenave, S., Brailly‐Tabard, S., Chanson, P., Trabado, S., Kaiser, U. B., & Young, J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac194 · Cited by 21
Grober, E. D., Krakowsky, Y., Khera, M., Holmes, D. T., Jc, L., Grantmyre, J. E., Patel, P., Bebb, R. A., Fitzpatrick, R., Campbell, J. D., et al. (2021) · Canadian Urological Association Journal · doi:10.5489/cuaj.7252 · Cited by 32
Patt, M., Beck, K. R., Marco, T. D., Jäger, M.-C., González‐Ruiz, V., Boccard, J., Rudaz, S. L., Hartmann, R. W., Salah, M., van Koppen, C. J., et al. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113781 · Cited by 28
Bio-Functional Sperm Parameters: Does Age Matter?
Condorelli, R. A., Vignera, S. L., Barbagallo, F., Alamo, A., Mongioì, L. M., Cannarella, R., Aversa, A., & Calogero, A. E. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.558374 · Cited by 24
Finkelstein, J. S., Lee, H., Burnett‐Bowie, S. M., Darakananda, K., Gentile, E. C., Goldstein, D. W., Prizand, S. H., Krivicich, L. M., Taylor, A. P., Wulczyn, K. E., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa318 · Cited by 25
Venkatesh, V. S., Grossmann, M., Zajac, J. D., & Davey, R. A. (2022) · Obesity Reviews · doi:10.1111/obr.13429 · Cited by 22
“tive evidence is available, the only unequivocal clinical indication for testosterone treatment is testosterone replacement for men with organic hypogonadism.(49,98)”
BackgroundPaetow, U., Bader, P., & Chemaitilly, W. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09864-z · Cited by 24
Corona, G., Rastrelli, G., Sparano, C., Carinci, V., Casella, G., Vignozzi, L., Sforza, A., & Maggi, M. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2337741 · Cited by 29
“Later on, the concept of non-classical hypo-gonadism (HG) or functional HG was partially incorporated in the clinical practice guidelines of the US Endocrine Society [10] as well as in the Australian one [11], as opposed to organic (classic) HG.”
BackgroundCan High Visceral Adiposity Index Be a Risk Factor for Sexual Dysfunction in Sexually Active Men?
Bolat, M. S., Kocamanoğlu, F., Özbek, L. M., Büyükalpelli, R., & Aşçı, R. (2020) · The Journal of Sexual Medicine · doi:10.1016/j.jsxm.2020.06.014 · Cited by 21
Molina‐Vega, M., Asenjo‐Plaza, M., García‐Ruiz, M. C., Varea‐Marineto, E., Casal‐Nievas, N., Álvarez‐Millán, J. J., Cabezas-Sánchez, P., Cardona, F., Queipo‐Ortuño, M. I., Castellano‐Castillo, D., et al. (2019) · Obesity · doi:10.1002/oby.22579 · Cited by 23
“In men, obesity is considered the major cause of hypogonadism, a clinical syndrome characterized by low serum total testosterone (TT) and/or free testosterone (FT) concentrations and associated symptoms and signs of testosterone deficiency (1).”
BackgroundMethodInfluentialHuman Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Rescue Testicular Aging
Luo, P., Chen, X., Gao, F., Xiang, A. P., Deng, C., Xia, K., & Gao, Y. (2024) · Biomedicines · doi:10.3390/biomedicines12010098 · Cited by 30
Hepcidin is not essential for mediating testosterone's effects on erythropoiesis
Guo, W., Schmidt, P. J., Fleming, M. D., & Bhasin, S. (2019) · Andrology · doi:10.1111/andr.12622 · Cited by 21
“Testosterone is an important regulator of erythropoiesis (Fonseca et al., 1998; Ornstein et al., 1999; Calof et al., 2005; Coviello et al., 2008; Hara et al., 2010; Bhasin et al., 2018).”
BackgroundSelf-citationOsteoporosis and bone metabolism in patients with Klinefelter syndrome
Grande, G., Graziani, A., Mambro, A. D., Selice, R., & Ferlin, A. (2023) · Endocrine Connections · doi:10.1530/ec-23-0058 · Cited by 29
Jones, T. H., Dobs, A. S., Randeva, H. S., Moore, W., & Parkin, J. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvad099 · Cited by 27
Effects of Testosterone Treatment on Quality of Life in Patients With Chronic Kidney Disease
Yeo, J. K., Koo, H., Yu, J., & Park, M. G. (2020) · American Journal of Men s Health · doi:10.1177/1557988320917258 · Cited by 25
“Although more research is necessary on LUTS in CKD patients with TD, the opinion stated in the current guidelines is that in general, testosterone treatment does not greatly affect LUTS induced by BPH (Bhasin et al., 2018; Morgentaler et al., 2019).”
BackgroundKimura, D. C., Argeri, R., Castro, C. H. D. M., Dias-da-Silva, M. R., & Gomes, G. N. (2021) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13495 · Cited by 24
The Chronobiology of Hormone Administration: “Doctor, What Time Should I Take My Medication?”
Colonnello, E., Graziani, A., Rossetti, R., Voltan, G., Masi, D., Lubrano, C., Mariani, S., Watanabe, M., Isidori, A. M., Ferlin, A., et al. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf013 · Cited by 28
The antidepressant effect of testosterone: An effect of neuroplasticity?
Walther, A., Wasielewska, J. M., & Leiter, O. (2019) · Neurology Psychiatry and Brain Research · doi:10.1016/j.npbr.2019.05.004 · Cited by 22
Environmental fate and toxicity of androgens: A critical review
Huanyu, T., Jianghong, S., Wei, G., Jiawei, Z., Ge, H. M., & Yunhe, W. (2022) · Environmental Research · doi:10.1016/j.envres.2022.113849 · Cited by 23
Testosterone Replacement Therapy: A Narrative Review with a Focus on New Oral Formulations
Bhat, S. Z., & Dobs, A. S. (2022) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2022.18.2.133 · Cited by 26
“The Endocrine Society guidelines thus recommend an individualized treatment approach with a detailed discussion of risks in this patient population, even those patients with a hypogonadal biochemical and symptom profile.(21)”
BackgroundMethodInfluentialBathina, S., & Armamento‐Villareal, R. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1168687 · Cited by 36
Buratto, J., Kirk, B., Phu, S., Vogrin, S., & Duque, G. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.04.013 · Cited by 22
Approach to the Patient: Low Testosterone Concentrations in Men With Obesity
Muir, C. A., Wittert, G., & Handelsman, D. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf137 · Cited by 34
Male Sex Hormones, Metabolic Syndrome, and Aquaporins: A Triad of Players in Male (in)Fertility
Nunes, D. C., Ribeiro, J. C., Alves, M. G., Oliveira, P. F., & Bernardino, R. L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24031960 · Cited by 28
“that triggers it [46], where organic etiology is understood as local, static, and irreversible damage (such as physical damage at the HPG level generated by trauma, cancer and/or radiation) and functional etiology is understood as one or more systemic and reversible damage (usually associated with other diseases linke…”
BackgroundTesticular cancer survivorship: Long-term toxicity and management
Shrem, N. S., Wood, L. A., Hamilton, R. J., Kuhathaas, K., Czaykowski, P., Roberts, M. T., Matthew, A., Izard, J., Chung, P. W. M., Nappi, L., et al. (2022) · Canadian Urological Association Journal · doi:10.5489/cuaj.8009 · Cited by 26
Adrenal morphology and associated comorbidities in congenital adrenal hyperplasia
El‐Maouche, D., Hannah‐Shmouni, F., Mallappa, A., Hargreaves, C. J., Avila, N. A., & Merke, D. P. (2019) · Clinical Endocrinology · doi:10.1111/cen.13996 · Cited by 20
Chung, E., Jiang, H., Xin, Z. C., Kim, S. W., Moon, D. G., Yuan, Y., Nagao, K., Hakim, L., Chang, H., Mak, S. K., et al. (2023) · The World Journal of Men s Health · doi:10.5534/wjmh.230180 · Cited by 27
“Current guidelines support the use of gonadotropins in men with central hypogonadism when fertility is desired [58,59,60,64].”
BackgroundIndirli, R., Ferrante, E., Scalambrino, E., Profka, E., Clerici, M., Lettera, T., Serban, A. L., Vena, W., Pizzocaro, A., Bonomi, M., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa936 · Cited by 22
“For KS patients on testosterone replacement therapy, blood samples were taken 2 hours after application of testosterone transdermal gel, or at the end of the dosing interval in case of injectable long-acting testosterone undecanoate (24).”
BackgroundMethodVincentis, S. D., Decaroli, M. C., Fanelli, F., Diazzi, C., Mezzullo, M., Tartaro, G., Tagliavini, S., Santis, M. C. D., Roli, L., Milić, J., et al. (2022) · The Aging Male · doi:10.1080/13685538.2022.2039116 · Cited by 23
Ladjouze, A., & Donaldson, M. (2019) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2019.101295 · Cited by 26
Cruickshank, M., Hudson, J., Hernández, R. A., Aceves‐Martins, M., Quinton, R., Gillies, K., Aucott, L. S., Kennedy, C., Manson, P. D., Oliver, N. S., et al. (2024) · Health Technology Assessment · doi:10.3310/jryt3981 · Cited by 26
Self-citationThe effects of type 1 and type 2 diabetes mellitus on bone health in chronic kidney disease
Aleksova, J., Ebeling, P., & Elder, G. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01083-8 · Cited by 20
“Testosterone replacement therapy increases spinal and hip BMD in hypogonadal men, with safety profiles established over decades 138 .”
Madsen, M. C., den Heijer, M., Pees, C., Biermasz, N. R., & Bakker, L. E. H. (2022) · Endocrine Connections · doi:10.1530/ec-22-0112 · Cited by 26
Izumi, K., Iwamoto, H., Yaegashi, H., Nohara, T., Shigehara, K., Kadono, Y., Nanjo, S., Yamada, T., Ohtsubo, K., Yano, S., et al. (2021) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12716 · Cited by 19
“rum total and free testosterone levels were used for diagnosis of hypogonadism in the current study.(55,56) In addition, both total and free testosterone levels were not measured by the gold standard method, liquid chromatography–tandem mass spectrometry.”
MethodBenderradji, H., Barbotin, A., Leroy-Billiard, M., Prasivoravong, J., marcelli, F., Decanter, C., Robin, G., Mitchell, V. A., Rigot, J.-M., Bongiovanni, A., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac218 · Cited by 23
Long COVID and pituitary dysfunctions: a bidirectional relationship?
di Filippo, L., Franzese, V., Santoro, S., Doga, M., & Giustina, A. (2024) · Pituitary · doi:10.1007/s11102-024-01442-8 · Cited by 22
“…authors it was shown that more than 50% and almost 30% of men, at a 7-month and 12-month follow-up investigation after acute COVID-19, respec - tively, still presented with testosterone levels suggestive for biochemical hypogonadism ( 9.2 nmol/L as per Endocrine Society threshold [51 , 84, 85]).”
Influential
Metadata
- Authors
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A.
- Affiliations
- Brigham and Women's Hospital (US)
- Mayo Clinic (US)
- Baylor College of Medicine (US)
- Massachusetts General Hospital (US)
- University of Southern California (US)
- VA Puget Sound Health Care System (US)
- University of Pennsylvania (US)
- University of California, Los Angeles (US)
- University of Manchester (GB)
- Corresponding author
- Bhasin, Shalender
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2018-03-17
- Volume
- 103
- Issue
- 5
- Pages
- 1715-1744
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2791298691
- Cited by
- 1,736
- References
- 169
- Citations by year
- 2026: 263 · 2025: 196 · 2024: 198 · 2023: 199 · 2022: 240 · 2021: 221 · 2020: 201 · 2019: 157 · 2018: 56
- FWCI
- 126.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Keywords
- testosterone replacement therapy, male hypogonadism, androgen deficiency, sex hormone-binding globulin, secondary sexual characteristics, treatment monitoring, patient decision-making, pharmacokinetics, sleep apnea, thrombophilia, heart failure, lower urinary tract symptoms, fertility preservation
- MeSH terms
- Aged, Aged, 80 and over, Aging, Blood Chemical Analysis, Diagnostic Techniques, Endocrine, Endocrinology, Humans, Hypogonadism, Male, Middle Aged, Societies, Medical, Testosterone, Evidence-Based Medicine, Hormone Replacement Therapy, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.